Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$21.17 USD

21.17
859,315

-0.36 (-1.67%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

by Zacks Equity Research

Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.

Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.

Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 185.5% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ekta Bagri headshot

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Mayur Thaker headshot

January CPI Comes in Hot But Underlying Inflation Pressures Remain Cool

by Mayur Thaker

i still expect core inflation to remain subdued which should keep a lid on yields, but cracks in consumer health and valuations remain top concerns

Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?

by Zacks Equity Research

Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.

Kinjel Shah headshot

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.

Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?

by Zacks Equity Research

Intellia Therapeutics (NTLA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

by Zacks Equity Research

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

3 Biotechs With Promising Gene Therapies in the Spotlight

by Ekta Bagri

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate

by Zacks Equity Research

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update

by Zacks Equity Research

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia (NTLA) Focuses on Developing Gene-Editing Therapies

by Zacks Equity Research

Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.